Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Trading Update

22 Nov 2023 07:00

RNS Number : 2049U
Plant Health Care PLC
22 November 2023
 

PLANT HEALTH CARE plc

("Plant Health Care" or the "Company")

 

Trading update

 

Plant Health Care® (AIM: PHC.L), a leading provider of novel patent-protected biological products to global agriculture markets, is announcing an update on trading and the outlook for the full year to 31 December 2023 ("FY23").

 

Highlights

 

· Market conditions in the wider agriculture market have diminished over the course of the year, particularly in the recent months;

· Due to these challenging market conditions, particularly in the key USA end market, the Company now anticipates revenue in FY2023 to be in line with or show modest growth over the year ended 31 December 2022 ("FY22"); 

· The Company continues to make significant progress in obtaining new product registrations and widening geographic distribution, positioning the Company well for growth in 2024 and beyond;

· Trading in Brazil, Mexico and Europe broadly in line with market expectations.

 

As highlighted at the time of the Company's interim results in September 2023, market conditions for traditional agriculture input businesses were extremely challenging in the first half of the year, and the environment has continued to deteriorate over recent months. This has been particularly evident in the US; however, global markets, including Brazil, Europe and some Asian markets, have also been subdued, leading a number of companies across the sector to revise guidance on current year performance.

 

Pleasingly, Plant Health Care's trading in Brazil, Mexico and Europe has been broadly in line with market expectations in the second half of the year, in spite of these challenging market conditions. However, sales orders in the US have not materialised as originally anticipated as the Company's distribution partners in the region have gone through a significant inventory correction. This has, in large part, been driven by volatility in demand and price following the global COVID-19 pandemic, as well as the effects of an increasing interest rate environment and change in growers purchasing habits. Distributors are shifting demand from Q4 FY23 into H1 FY24 and are planning to manage lower levels of inventory for FY24. While inventories of the Company's products with distributors are not high, it is not immune to this structural change. In addition, regulatory delays in India and a number of other countries have resulted in delays to some product launches; whilst this is expected to have a limited impact on the Company in FY23, this is likely to affect performance more materially in FY24.

 

Accordingly, the Board now anticipates revenue for FY23 to show flat to modest growth over FY22, with the final result dependent on the timing of expected orders. Revenue in FY24 is now anticipated to be approximately 28% lower than market expectations of $23m, due to lower levels of inventory being maintained by the Company's distributors and regulatory delays in some territories. The Board intends to review operating expenses accordingly.

 

Against this backdrop, the pace of new product registrations and the widening of distribution partnerships into new geographies continues. Sales of Harpin£ are increasing in all of the Company's core markets, excluding the US market. Critically, the first products from the new PREtec platform are being well received in the market, with successful product launches across three continents. Although there are some delays to product launches, the growth trajectory is clear for the medium term. After more than 10 years and an investment in excess of $30m, PREtec product adoption is poised for a significant step up from distributors and end customers. Accordingly, the Board is confident that order intake will increase once our customers have corrected their inventory levels.

 

Jeff Tweedy, Chief Executive Officer, commented:

 

"Sales of Plant Health Care products experienced significant growth in all regions with the exception of the US market. Deteriorating market conditions driven by distributor destocking of channel inventories impacted PHC sales in the US. Registration delays have impacted our 2024 outlook; however, we remain positive on the revenue growth opportunities for our technology. PHC now markets PREtec on three continents and we anticipate the launch of Teikko in Brazil during the 2024/2025 growing season."

 

For further information, please contact:

 

Plant Health Care plc

Tel: +1 919 926 1600

Jeff Tweedy, CEO

 

Cavendish Capital Markets Limited - Nomad & Broker

Tel: +44 (0) 131 220 9771

Neil McDonald / Peter Lynch

 

 

About Plant Health Care

Plant Health Care offers products to improve the health, vigour and yield of major field crops such as corn, soybeans, potatoes, and rice, as well as specialty crops such as fruits and vegetables. We operate globally through subsidiaries, distributors and supply agreements with major industry partners. Our innovative, patent-protected biological products help growers to protect their crops from stress and diseases, and to produce higher quality fruit and vegetables, with a favourable environmental profile.

 

Find out more at www.planthealthcare.com

 

This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUAORROSUAUUA
Date   Source Headline
27th Sep 20075:19 pmRNSDirector/PDMR Shareholding
27th Sep 20077:01 amRNSPlacing
24th Sep 20077:03 amRNSHalf Year Results
24th Sep 20077:02 amRNSMyconate Trial Results
31st Aug 200710:14 amRNSTotal Voting Rights
28th Aug 20071:00 pmRNSStock Award
23rd Aug 200710:14 amRNSNotice of Results
13th Aug 20074:15 pmRNSAIM Rule 26 Information
13th Aug 200711:55 amRNSHolding(s) in Company
13th Aug 20078:49 amRNSHolding(s) in Company
31st Jul 200711:39 amRNSTotal Voting Rights
27th Jul 20077:01 amRNSN-Hibit Trial Results
25th Jul 20071:38 pmRNSAdditional Listing
23rd Jul 200711:35 amRNSDirector/PDMR Shareholding
2nd Jul 20072:25 pmRNSTotal Voting Rights
27th Jun 20077:01 amRNSProduct Update
11th Jun 20075:53 pmRNSHolding(s) in Company
8th Jun 20075:03 pmRNSAGM Statement
4th Jun 20077:31 amRNSTotal Voting Rights
17th May 20077:01 amRNSBoard Change
14th May 20077:00 amRNSNotice of AGM
1st May 20073:25 pmRNSTotal Voting Rights
26th Apr 20079:23 amRNSAnnual Report and Accounts
19th Apr 20071:22 pmRNSDirector/PDMR Shareholding
18th Apr 20075:42 pmRNSDirector/PDMR Shareholding
16th Apr 20077:02 amRNSFinal Results
16th Apr 20077:02 amRNSSuccessful Trial Results
30th Mar 20074:54 pmRNSTotal Voting Rights
30th Mar 20074:51 pmRNSHolding(s) in Company
23rd Mar 20076:19 pmRNSHolding(s) in Company
13th Mar 20079:01 amRNSNotice of Results
5th Mar 20075:36 pmRNSExercise of Options
5th Mar 20075:20 pmRNSHolding(s) in Company
5th Mar 20078:04 amRNSHolding(s) in Company
1st Mar 20073:33 pmRNSTotal Voting Rights
1st Mar 20077:04 amRNSRe Acquisition
15th Feb 20079:04 amRNSPartnership
8th Feb 200712:13 pmRNSAdditional Listing
6th Feb 20075:52 pmRNSAdditional Listing
5th Feb 200710:19 amRNSHolding(s) in Company
2nd Feb 20078:40 amRNSHolding(s) in Company
31st Jan 20077:01 amRNSDirector/PDMR Shareholding
24th Jan 200712:01 pmRNSHolding(s) in Company
19th Jan 200712:24 pmRNSTotal Voting Rights
18th Jan 20076:06 pmRNSDirector/PDMR Shareholding
17th Jan 20077:01 amRNSMyconate Agreement
17th Jan 20077:01 amRNSTrading Statement
15th Jan 200710:42 amRNSMyconate Update
5th Jan 20079:01 amRNSExercise of Options
20th Dec 20064:14 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.